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ABSTRACT The association of receptor tyrosine kinases is a key step in the initiation of growth factor-mediated sig-
naling. Although the ligand-induced dimerization of inactive, monomeric receptors was the central dogma of receptor tyrosine
kinase activation for decades, the existence of larger oligomers is now accepted. Both homoassociations and hetero-
associations are of extreme importance in the epidermal growth factor (EGF) receptor family, leading to diverse and robust
signaling. We present a statistically reliable, ﬂow-cytometric homo-ﬂuorescence resonance energy transfer method for the
quantitative characterization of large-scale receptor clusters. We assumed that a fraction of a certain protein species is
monomeric, whereas the rest are present in homoclusters of N-mers. We measured ﬂuorescence anisotropy as a function
of the saturation of ﬂuorescent antibody binding, and ﬁtted the model to the anisotropy data yielding the fraction of
monomers and the cluster size. We found that ErbB2 formed larger homoclusters than ErbB1. Stimulation with EGF
and heregulin led to a decrease in ErbB2 homocluster size, whereas ErbB1 homoclusters became larger after EGF
stimulation. The activation level of ErbB2 was inversely proportional to its homocluster size. We conclude that homo-
clusters of ErbB1 and ErbB2 behave in a fundamentally different way. Whereas huge ErbB2 clusters serve as a reservoir of
inactive coreceptors and dissociate upon stimulation, small ErbB1 homoclusters form higher-order oligomers after ligand
binding.
INTRODUCTION
The dimerization of membrane proteins is believed to play a
fundamental role in the activation of receptor tyrosine kinases
(RTKs). The groundbreaking discovery of the importance
of receptor oligomerization in the 1970s (1) was supported
by the crystal structure of the epidermal growth factor (EGF)
receptor (2). The ligand-induced dimerization of RTKs be-
came textbook dogma, and because of the limited potential
of classical molecular biological methods to detect clusters
composed of more than two receptors, larger oligomers were
neglected. Promiscuous homoassociation and heteroasso-
ciation are prominent features of the EGF receptor family
(also known as the ErbB family) of RTKs consisting of four
members, i.e., ErbB1 (EGF receptor) and ErbB2–4 (3–5).
The prototypical RTK, ErbB1, is believed to undergo ligand-
induced homodimerization and activation (2). The ligandless
coreceptor, ErbB2, is activated either by heterodimerization
with other ErbB proteins or by overexpression-driven con-
stitutive homoassociation (6,7). The kinase-deﬁcient ErbB3
receptor can only transmit signals by heterodimerization,
primarily with ErbB2 (8). The simplistic view of inactive
monomers and active dimers was complicated by discovering
preformed clusters of inactive ErbB receptors (9–12). A fur-
ther twist in the story involved the repeated identiﬁcation
of large receptor clusters in both quiescent and stimulated
cells. Fluorescence correlation microscopy revealed clusters
containing 10 to 30 EGF receptors (13). Webb et al. also
reported on 4 to 5 EGF receptors/cluster, based on the
number of photobleaching steps in single-molecule ﬂuores-
cence time traces (14). A combined ﬂuorescence resonance
energy transfer (FRET)-correlation microscopic study con-
ﬁrmed the existence of ErbB1 tetramers and large homo-
clusters containing 15 to 30 receptors (15). The EGF receptor
was shown to undergo activation-induced dimer-tetramer
transition (16), whereas ErbB3 was shown to behave differ-
ently. It forms homoclusters whose upper size limit is a
dodecamer. Heregulin, the ligand of ErbB3, reverses the
homoassociation of ErbB3 (17,18). The ErbB3 molecules
that break free from the homoclusters most probably hetero-
associate with ErbB2, because kinase-dead ErbB3 can
only transmit signals by heteroassociating with other ErbB
proteins. Scanning near-ﬁeld optical microscopy revealed
clusters containing ;1000 ErbB2 molecules in microdo-
mains with a diameter of ;500 nm, which increased upon
stimulation (19). These reports present convincing evidence
for the existence and importance of large-scale protein
associations.
Apart from biochemical methods, which are usually
semiquantitative and are not appropriate for the investigation
of living cells, several approaches are available for the quan-
titative characterization of large-scale receptor associations
in intact cells. Fluorescence correlation spectroscopy (13,15),
single-molecule imaging (14,20), and measurement of the
rotational diffusion rate (21) were applied for this purpose.
Probably the most widely used quantitative technique for
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the analysis of protein-clustering is FRET, in which energy
is transferred in a nonradiative fashion from an excited donor
molecule to a nearby acceptor. The rate of FRET varies in-
versely with the sixth power of the donor-acceptor separa-
tion, turning it into a useful distance-measuring tool (22).
When the process takes place between a donor and a spec-
troscopically different acceptor, it is termed hetero-FRET.
Although a careful analysis of hetero-FRET signals can re-
veal the stoichiometry of association, the physical interaction
in hetero-FRET takes place between a single pair of donor
and acceptor, limiting the potential of hetero-FRET mea-
surements to analyze large protein clusters (16,23,24). In
homo-FRET, the interaction takes place between a donor and
a spectroscopically identical ‘‘acceptor’’ which can serve as
the donor in the next homo-FRET step. This sequential aspect
of the interaction is reﬂected in the term energy migration
FRET (emFRET), used as a synonym for homo-FRET (10).
Because energy is distributed among the interacting mole-
cules, homo-FRET can be used for the quantitative analysis
of large protein clusters. Because the only manifestation of
homo-FRET is decreased ﬂuorescence anisotropy, Runnels
and Scarlata derived a formula for the steady-state anisotropy
of clusters of N molecules (25). Steady-state anisotropy is
ambiguously related to homo-FRET, because factors other
than energy transfer can also change its value. Therefore,
anisotropy is either measured in the time domain (23), or its
dependence on ﬂuorophore density is analyzed to enumerate
the number of interacting ﬂuorophores. The latter strategy
was applied by measuring the increase in anisotropy as a
function of ﬂuorophore photobleaching (10,26,27). Alter-
natively, the loss of homo-FRET occurring at red-edge ex-
citation was used to isolate the contribution of homo-FRET to
the measured anisotropy in microscopy (28).
Microscopy suffers from low statistical accuracy because
of the limited number of cells measured. Flow cytometry
offers superior statistics, without the capability to quantitate
photobleaching. Here we present a ﬂow-cytometric method
for the measurement of homo-FRET, based on varying the
amount of saturation of antibody binding to cell-surface re-
ceptors. We derived a formula for the dependence of ﬂuo-
rescence anisotropy on the fraction of monomers and on the
number of proteins in a single cluster, and ﬁtted the model to
anisotropy data measured on cells labeled with anti-ErbB1 or
anti-ErbB2 antibodies. The data presented here provide sig-
niﬁcant new insights into the large-scale association prop-
erties of ErbB receptors.
MATERIALS AND METHODS
Cell lines
The human breast-cancer cell line SKBR-3 and the human epithelial carci-
noma cell line A431 were obtained from the American Type Culture Col-
lection (Rockville, MD), and were grown according to their speciﬁcations.
For ﬂow cytometry, cells were harvested by trypsinization.
Antibodies and growth factors
The anti-ErbB1 monoclonal antibody EGFR455, which does not block the
binding of EGF, was produced by hybridoma 455 obtained from the Euro-
pean Collection of Cell Cultures (Wiltshire, UK). Mab528 against ErbB1,
competing with EGF binding, was prepared from the supernatant of the HB-
8509 hybridoma cell line obtained from American Type Culture Collection.
Antibodies were puriﬁed from hybridoma supernatants, using protein A af-
ﬁnity chromatography. The anti-ErbB2 antibody, trastuzumab (Herceptin),
was purchased from Roche (Budapest, Hungary). The conjugation of pri-
mary antibodies with AlexaFluor (Molecular Probes, Eugene, OR) dyes was
performed according to the manufacturer’s speciﬁcations. The OP15 mon-
oclonal antibody against an intracellular epitope of ErbB2 was obtained from
Calbiochem-Merck Biosciences (Schwalbach, Germany). Ab-18, recogniz-
ing the activated, tyrosine-phosphorylated form of ErbB2, was purchased
from Lab Vision (Fremont, CA). Pertuzumab (Omnitarg) was a gift from
Genentech (South San Francisco, CA). EGF and heregulin-b1 were obtained
from R&D Systems (Minneapolis, MN). The Alexa488-conjugated and
Alexa546-conjugated F(ab9)2 fragments of goat anti-mouse immunoglobulin
G (IgG) and the Cy3-labeled F(ab9)2 fragment of goat anti-human IgG were
from Molecular Probes/Invitrogen (Eugene, OR).
Labeling of cells with antibodies
Freshly harvested cells were washed twice in ice-cold phosphate-buffered
saline (PBS; pH 7.4), and the cell pellet containing ;1 million cells was
suspended in 100 mL of Hanks’ buffer with 1 mg/mL bovine serum albumin
(BSA). For homo-FRET measurements, ErbB1 or ErbB2 receptors were
labeled with different ratios of unlabeled and Alexa488-labeled antibodies
for 30min on ice in the dark. The total concentration of unlabeled and labeled
antibodies was 50 mg/mL, and the fraction of labeled antibody varied from
0% to 100%, with increments of 10%. Labeled cells were washed twice with
cold PBS and ﬁxed with 1% formaldehyde in PBS. All samples were kept at
4C before performing measurements, to prevent the modulation of anti-
body-induced receptor clustering.
To determine the limiting anisotropy of Alexa488-conjugated antibodies,
ErbB1 or ErbB2 receptors were incubated with 50 mg/mL donor-conjugated
antibody (Alexa488-trastuzumab, Alexa488-Mab528, or Alexa488-EGFR455)
for 30 min on ice in the dark. After washing, the samples were divided into
ﬁve parts, which were labeled by different concentrations (0.5 to 9mg/mL) of
acceptor-conjugated secondary antibody (Cy3-labeled F(ab9)2 fragments of
goat anti-human IgG in the case of Alexa488-trastuzumab, or Alexa546-
conjugated F(ab9)2 fragments of goat anti-mouse IgG in the case of Alexa488-
Mab528 and Alexa488-EGFR455) for 30 min on ice in the dark. Labeled
cells were washed and ﬁxed with 1% formaldehyde in PBS.
For the measurement of ErbB2 phosphorylation, quiescent and stimulated
cells were ﬁxed with 3.7% formaldehyde in PBS for 30 min on ice, and
washed twice with cold Tris-buffer (100 mM Tris1 100 mM NaCl; pH 7.4)
to quench unreacted formaldehyde. Each sample was divided into two parts,
whichwere separately labeledwith OP15 (10mg/mL) andAb-18 (10mg/mL)
against ErbB2 and phosphorylated ErbB2 (p-ErbB2), respectively. Labeling
was performed in PBS-BSA-TX permeabilization buffer (0.1% (v/v) Triton
X-100, 1 mg/mL BSA in PBS, pH 7.4) for 30 min on ice. After washing with
cold PBS-BSA-TX, cells were labeled with Alexa488-conjugated F(ab9)2
fragments of goat anti-mouse IgG for 30 min on ice in the dark. Labeled cells
were washed twice, resuspended in 1% formaldehyde, and analyzed by ﬂow
cytometry.
Treatment of cells with EGF, heregulin,
and pertuzumab
Cells were starved for 24 h before the experiment inmedium containing 0.1%
fetal calf serum (FCS). Freshly harvested cells were washed twice in cold
PBS, and resuspended in 100mL Hanks’ buffer supplemented with 1 mg/mL
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BSA. Pretreatment with 20 mg/mL pertuzumab was performed for 15 min at
37C. Control and pertuzumab-pretreated cells were stimulated with 100 ng/
mL EGF or 100 ng/mL heregulin for 15 min at 37C, and subsequently used
for homo-FRET measurements, as described above.
Flow cytometry and data analysis
Cell-by-cell ﬂuorescence anisotropy measurements were performed in the
L-format arrangement on a FACSVantage SE instrument with a DiVa option
(Becton Dickinson, Franklin Lakes, NJ). Alexa488 was excited by a verti-
cally polarized 488-nm beam, which was produced by letting the 488-nm line
of an Ar ion laser pass through a half-wave plate retarder (model 481AS,
Newport, Irvine, CA). The angle of the half-wave plate corresponding to
vertical polarization was adjusted by light-scatter measurements. Emitted
photons passed through a 530 6 15 nm band-pass ﬁlter, followed by a
broadband polarizing beam-splitter cube (model 10FC16PB.3, Newport)
separating the vertically and horizontally polarized components. Two po-
larized ﬂuorescence intensities, designated by Ivv and Ivh, were detected,
where the ﬁrst and second indices refer to the polarization directions of the
exciting laser light and of ﬂuorescence, respectively. For the determination of
the G-factor, cells were excited by horizontally polarized light produced by
rotating the half-wave plate by 45 relative to its vertical position. The two
polarized ﬂuorescence intensities recorded with horizontal excitation are
labeled by Ihv and Ihh. After subtracting the intensity of unlabeled cells from
each polarized intensity, the G-factor compensating for the different sensi-
tivities of the detection system to vertically and horizontally polarized light,
the total ﬂuorescence intensity (Itot), and the ﬂuorescence anisotropy (r) were
calculated as follows:
G ¼ Ihv
Ihh
(1)
Itot ¼ Ivv1 a3G3 Ivh (2)
r ¼ Ivv  G3 Ivh
Itot
: (3)
The inﬂuence of high-aperture ﬂuorescence collection on the determined
anisotropy was compensated according to Jovin (constant a in Eq. 2) (29).
Fifty thousand cells were recorded from each sample containing a certain
fraction of labeled and unlabeled antibodies. Anisotropy was calculated on a
cell-by-cell basis according to Eq. 3. Cells were gated on the forward scatter-
side scatter dot plot and on the total ﬂuorescence intensity-anisotropy dot
plot, using ReFlex software (available at http://www.freewebs.com/cytoﬂex)
(30);;10,000 to 20,000 cells were gated out, leaving 30,000 to 40,000 cells
for calculating the average ﬂuorescence intensity and anisotropy values.
Anisotropy was plotted against saturation, and the graph from a single
experiment was ﬁtted by Eq. 7 (see Therory, below). Fitting andMonte Carlo
simulation were performed using Mathematica (Wolfram Research,
Champaign, IL). Cluster size and monomer percentage values reported in
the text and in Table 1 were calculated by averaging the values obtained from
the ﬁtting of three separate experiments. The sequence of data collection and
processing is summarized in Fig. 1.
Hetero-FRET efﬁciency was determined using a FACSVantage SE ﬂow
cytometer with a DiVa option, with dual-laser excitation at 488 and 532 nm.
The donor (Alexa488) and FRET signals were excited at 488 nm and de-
tected at 530 6 15 nm and 585 6 21 nm, respectively. Direct acceptor
emission (Alexa546 or Cy3) was detected at 585 6 21 nm upon 532-nm
excitation with a diode-pumped, solid-state laser. The FRET efﬁciency was
determined on a cell-by-cell basis, using ReFlex software as described pre-
viously (30,31).
Theory
Homo-FRET efﬁciency changes as a function of ﬂuorophore density. Pre-
viously, photobleaching was used to create a range of ﬂuorophore densities
(10,27), but the same approach is not applicable in ﬂow cytometry. Instead,
we labeled cell-surface proteins with a mixture of ﬂuorophore-labeled and
unlabeled antibodies against the same epitope, so that the total antibody
concentration saturated the available binding sites. In this way, the fraction of
epitopes to which ﬂuorophore-tagged antibody bound (saturation designated
by s in the equations) was approximately equal to the fraction of labeled
antibody in the mixture. The amount of saturation (s) was estimated by di-
viding the ﬂuorescence intensities of each sample with that of the brightest
one. We assumed that a fraction (mon) of the proteins is monomeric, and that
the rest (1-mon) are present in homoclusters of N-mers. Essentially, any
protein unable to undergo homo-FRET is regarded as monomeric in the
calculations, e.g., a labeled protein in a heterodimeric complex, because it
does not interact with another protein of the same kind. The probability that k
out of N proteins is labeled by a ﬂuorescent antibody in the N-mer when the
fraction of labeled proteins is s is described by the binomial distribution:
Ps;k;N ¼
 
N
k
!
s
kð1 sÞNk: (4)
The anisotropy of such a homocluster according toRunnels and Scarlata (25) is
rk ¼ r1ð11 d
6Þ
11 k d6
1 rFRET
ðk  1Þd6
11 k d6
; (5)
where r1 and rFRET are the anisotropies of an initially excited molecule and
that of a molecule excited by homo-FRET, respectively, and d is the distance
between the ﬂuorophores in the clusters normalized to R0. The determination
of r1 will be explained in Results. We assumed a complete depolarization of
ﬂuorescence emitted by every ﬂuorophore except for the initially excited
TABLE 1 Cluster sizes and monomer percentages of ErbB1 and ErbB2
ErbB1 ErbB2
Cluster size Monomer % Cluster size Monomer %
Starved Control 4 6 1 88 6 4 111 6 12 60 6 5
EGF 11 6 2 71 6 3 71 6 6 61 6 4
Heregulin – – 32 6 4 59 6 5
Pertuzumab – – 84 6 7 70 6 4
Pertuzumab 1 heregulin – – 73 6 6 58 6 3
Nonstarved Control 7 6 1 75 6 4 9 6 2 53 6 3
Pertuzumab – – 30 6 4 55 6 3
ErbB1 and ErbB2 were labeled by Alexa488-EGFR455 and Alexa488-trastuzumab, respectively. The cluster size and monomer percentage are shown on
cells pretreated and stimulated in different ways. Means (6 SE) were calculated from the ﬁtted cluster size and monomer percentage values obtained from
three independent experiments. Cluster size is the average number of ErbB1 or ErbB2 proteins in the cluster. Monomer percentage is the fraction of ErbB1 or
ErbB2 present outside homoclusters (either as monomers or heterodimers with other proteins).
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one, and therefore, rFRET¼ 0 (25). Although membrane proteins are ordered
in the plane of the membrane and their rotation is slow on the timescale of
ﬂuorescence, bending of the antibody around the epitope, segmental motions
of the Fab arms around the Fc portion, and rapid rotation of the antibody-
bound ﬂuorophore make the system practically randomly oriented. If the
assumption of rFRET¼ 0 is incorrect, it leads to an underestimation of cluster
size or an overestimation of monomer percentage. The resultant anisotropy of
the mixture of monomers andN-mers is the intensity-weighted average of the
individual anisotropies (32):
rs;k;N ¼
ð1 monÞ +
N
k¼0
Ps;k;N
k
N
rk1 s3mon3 r1
ð1 monÞ +
N
k¼0
Ps;k;N
k
N
1 s3mon
; (6)
where k/N is a correction factor normalizing the sum of the ﬂuorescence
intensity of N-mers and monomers to unity. Multiplication by k is necessary
to weigh the anisotropy values according to the ﬂuorescence intensity.
Without dividing by N, the ﬂuorescence intensity of clusters would be
overweighted by a factor ofN. By combining Eqs. 4–6, the total anisotropy is
given by the following formula:
Equation 7 predicts that the total anisotropy is constant, if only mono-
mers are present, and that the anisotropy is a linear function of saturation
if homoclusters are dimers. The higher the number of proteins in a homo-
cluster, the steeper the anisotropy declines at low values of saturation
(Fig. 2). Equation 7 was ﬁtted to the measured anisotropy-saturation
plot, with mon and N as the ﬁtting parameters (Fig. 3). We then calcu-
lated the standard deviation of the anisotropy values and generated
250 random data sets, with mean and standard deviation values equal
to the measured data. These random data sets were also ﬁtted by Eq. 7,
FIGURE 1 Data collection, gating, and processing strategy to calculate cluster size and monomer percentage from ﬂow-cytometric anisotropy
measurements; 50,000 cells, labeled by a mixture of labeled and unlabeled antibodies, were measured. Cells were ﬁrst gated on the forward scatter-side
scatter (FSC-SSC) dot plot (A), followed by gating on the anisotropy versus total ﬂuorescence intensity dot plot (B). Data were recorded with 18-bit resolution,
but were rescaled for the dot plots. The thick dashed line in B indicates the ﬂuorescence intensity of unlabeled cells. Gates are represented by shaded polygons.
The position of the gates was identical for every sample with a different concentration of the labeled antibody measured on the same day. The lower threshold
of total ﬂuorescence intensity was visually adjusted to gate out dim cells whose anisotropy had a large variation, and the threshold was kept constant for all
samples. The average anisotropy was calculated, yielding a total intensity-anisotropy data point on the graph showing the dependence of anisotropy on the
concentration of labeled antibody (saturation, in C). Equation 7 was ﬁtted to the anisotropy-saturation plot, yielding the estimated cluster size and monomer
percentage. The results of three independent experiments were averaged. Anisotropy was assumed to be normally distributed, and its error was estimated. The
mean and error values were used to generate 250 random data sets, similar to the one shown in C. Every data set was ﬁtted, yielding 250 pairs of cluster sizes
and monomer percentages from which frequency histograms were generated.
rs;k;N ¼
ð1 monÞ +
N
k¼0
 
N
k
!
s
kð1 sÞNk k
N

r1
ð11 d6Þ
11 k d6
1 rFRET
ðk  1Þd6
11 k d6
" #
1 s3mon3 r1
ð1 monÞ +
N
k¼0
 
N
k
!
s
kð1 sÞNk k
N
1 s3mon
: (7)
Large-Scale Association of ErbB Proteins 2089
Biophysical Journal 95(4) 2086–2096
yielding 250 values for cluster size (N) and monomer percentage
(mon). The distribution of both parameters was calculated, and the
graphs for ErbB1 and ErbB2 under different conditions are given in Figs. 5
and 6.
RESULTS
Determination of the limiting anisotropy of
antibody-bound ﬂuorophores
We approximated the anisotropy of the initially excited
ﬂuorophore (r1) by the limiting anisotropy of the antibody-
bound ﬂuorophore (r0). The emission anisotropy of a ﬂuo-
rophore (r) changes as a function of its rotational correlation
time and ﬂuorescence lifetime, according to the Perrin
equation:
1
r
¼ 1
r0
11
tfl
trot
 
; (8)
where tﬂ is the ﬂuorescence lifetime and trot is the ap-
parent rotational correlation time of the ﬂuorophore, tak-
ing into account all depolarizing processes taking place
during the excited-state lifetime (rotational diffusion of
the antibody, and segmental motion of parts of the anti-
body and that of the ﬂuorophore). The apparent limiting
anisotropy of the ﬂuorophore is given as r0. Because hetero-
FRET decreases the ﬂuorescence lifetime, a Perrin plot
can be constructed by varying the hetero-FRET efﬁciency
(33):
tfl ¼ ð1 EÞtD0 1
r
¼ 1
r0
11
ð1 EÞtD
trot
 
; (9)
where tD is the lifetime of the ﬂuorophore (‘‘donor’’) in the
absence of FRET. The y-intercept of a line ﬁtted on the 1/r
versus 1  E plot is the reciprocal of the limiting anisotropy.
To create a range of donor ﬂuorescence lifetimes, i.e., FRET
efﬁciencies, cells labeled with saturating concentrations of
the donor-tagged antibody were labeled by different concen-
trations of an acceptor-tagged secondary antibody. Both the
hetero-FRET efﬁciencies and the ﬂuorescence anisotropies
of the donor were measured and displayed on a Perrin plot
(Fig. 4), and the limiting anisotropies were calculated for
each of the IgGs and Fab fragments (r0,A488-trastuzumab ¼
0.268; r0,A488-trastuzumab Fab ¼ 0.289; r0,A488-Mab528 ¼ 0.226;
and r0,A488-Mab EGFR455 ¼ 0.170).
Calculation of the separation distance between
two antibodies bound to a homocluster
The distance between two antibodies bound to homoclusters
has to be known in units of R0. We ﬁrst determined R0 for the
Alexa488 homo-FRET case, according to the following
formula in units of nm:
R0 ¼ 8:83 1018ðJ3CD3 n43 k2Þ1=6: (10)
The overlap integral (J) was calculated from spectra available
from the Invitrogen web site, according to the following
formula:
FIGURE 2 Theoretical curves show the dependence of ﬂuorescence
anisotropy on the saturation of binding sites as a function of cluster size
and monomer percentage. The anisotropy of ﬂuorescence antibodies as
a function of the saturation of binding sites was determined according to
Eq. 7, assuming a limiting anisotropy of 0.27. The calculation was per-
formed for several cluster sizes, with no monomers present (numbers
indicate number of proteins in the homocluster: d, 1; s, 2; n, 3; h, 4;
:, 5; D, 10;¤, 20), and for the case when half of the proteins are monomers
(), 10; w, 20).
FIGURE 3 Fitting of the anisotropy model to ErbB1 and ErbB2 anisot-
ropy data. Starved (d) and heregulin-stimulated (n) SKRB-3 cells were
labeled with a mixture of unlabeled and Alexa488-labeled trastuzumab.
Starved (e) and EGF-stimulated (,) A431 cells were labeled with a mixture
of unlabeled and Alexa488-labeled EGFR455. The anisotropy of samples
was determined and plotted as a function of saturation of binding sites. The
lines show the results of ﬁtting according to Eq. 7.
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J ¼
Z N
0
fDðlÞ eAðlÞ l4 dl; (11)
where fD and eA are the normalized ﬂuorescence spectrum
and the molar absorption coefﬁcient of Alexa488, respec-
tively. The quantum yield (CD) of Alexa488 was previously
reported to be 0.6 (34). We assumed a value of 1.4 and 2/3 for
the index of refraction (n) and the orientation factor (k2),
respectively, yielding 4.8 nm for the R0 between two
Alexa488 molecules undergoing homo-FRET. The hetero-
FRET efﬁciency for ErbB2 homodimerization, measured by
Cy3-trastuzumab and Cy5-trastuzumab, was found to be
20% (35). Using 5 nm as the R0 between Cy3 and Cy5 (35),
the above FRET efﬁciency corresponds to an average sepa-
ration distance of 6.29 nm, according to the formula:
R ¼ R0
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 E
E
6
r
; (12)
where E is the FRET efﬁciency. Therefore, the average
separation between two trastuzumab molecules (d in Eq. 7) in
units of R0 is 6.29 nm/4.8 nm ¼ 1.3 3 R0. Using the same
approach, the average distance between two EGFR455 an-
tibodies and between twoMab528 antibodies was found to be
1.1 3 Ro and 1.4 3 Ro, respectively.
Stimulation of ErbB2 leads to a decrease
in its cluster size
The homo-FRET model described above was used for eval-
uation of the homocluster formation of ErbB1 and ErbB2
in quiescent and stimulated cells. SKBR-3 cells expressing
;8 3 105 ErbB2 proteins (36) were starved in low-serum
medium (0.1% FCS) for 24 h, and the percentage of mono-
meric ErbB2 and the cluster size of homoassociated ErbB2
were determined; ;60% of ErbB2 molecules were mono-
meric, but the rest formed huge clusters composed of ;110
ErbB2 proteins (Fig. 5, A and B; Table 1). Stimulation of
starved cells with EGF or heregulin did not change the per-
centage of monomers signiﬁcantly, but led to a substantial
decrease in the size of ErbB2 homoclusters. The effect of
heregulin was more pronounced than that of EGF. Pretreat-
ment of cells with pertuzumab led to a slight increase in the
percentage of ErbB2 monomers and to a signiﬁcant decrease
in cluster size (Fig. 5, C and D; Table 1). Pertuzumab pre-
treatment practically abolished the effect of heregulin on
ErbB2 cluster size, although the effect of heregulin on ErbB2
monomer percentage was unaffected. If cells were not starved
before the experiment, the percentage of monomers was
lower than in starved cells, and the size of ErbB2 homo-
clusters was even smaller than in heregulin-stimulated or
EGF-stimulated cells. To examine the possible effect of la-
beling with bivalent antibodies on ErbB2 clustering, non-
starved SKBR3 cells (cultured in the presence of 10% FCS)
were labeled with a mixture of Alexa488-labeled and un-
labeled Fab fragments of trastuzumab. The observation that
both the cluster size and monomer percentage were identical
in cells labeled with trastuzumab IgG and Fab implies that
labeling with bivalent IgG does not modify the clustering
properties of ErbB2 (Fig. 5, E and F). Treatment of non-
starved cells with pertuzumab signiﬁcantly increased the size
of ErbB2 homoclusters, without an effect on monomer per-
centage (Fig. 5, E and F; Table 1). We concluded that ErbB2
is homoclustered to different degrees in quiescent and stim-
ulated cells, and its cluster size changes as a function of its
activation state.
Stimulation of ErbB1 induces an
increase in its cluster size
Next, we compared the homoclustering properties of ErbB1
to those of ErbB2. The ﬂuorescence anisotropy of Alexa488-
EGFR455 antibody was evaluated in A431 cells starved in
low-serummedium for 24 h. The A431 cell line expresses;2
million copies of ErbB1 per cell (37); ;90% of ErbB1 was
monomeric, and the remaining ;10% formed homoclusters
containing ;4 ErbB1 molecules (Fig. 6; Table 1). Stimula-
tion of cells with EGF reduced the monomer percentage of
ErbB1 to ;70%, and increased its homocluster size to ;10
receptors/homocluster. In cells cultured under normal serum
conditions (10% FCS), the homocluster size of ErbB1 was
larger, and the monomer percentage was lower, than in
starved cells. The experiments were repeated with A431 cells
labeled with Mab528 against ErbB1. Because Mab528 ste-
rically blocks the EGF binding site, the labeling of EGF-
stimulated cells by Mab528 would have been unpredictable.
Therefore, only cells cultured in the presence of 0.1% and
10% FCS were measured. Both the ErbB1 monomer per-
FIGURE 4 Determination of limiting anisotropy. Cells were labeled
with saturating concentration of the primary antibody (Alexa488-tagged
trastuzumab, d; EGFR455, n; or Mab528, ,) followed by secondary
labeling by Cy3-anti-human F(ab9)2 or Alexa546-anti-mouse F(ab9)2. The
ﬂuorescence anisotropy and the hetero-FRET efﬁciency were calculated for
each sample, and the y-intercept of the line ﬁtted on the Perrin plot yielded
the reciprocal of the limiting anisotropy.
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centages and the cluster sizes determined by Mab528 label-
ing were practically identical to those obtained by EGFR455
(cluster size, 4 and 10 in the presence of 0.1% and 10% FCS,
respectively; monomer percentage, 90% and 78% in the pres-
ence of 0.1% and 10% FCS, respectively). We concluded that
ErbB1 forms substantially smaller homoclusters than ErbB2,
and that its cluster size increases in response to activation.
ErbB2 activation state and cluster size are
inversely related to each other
Factors known to induce ErbB2 activation (EGF, heregulin,
and serum) decreased its homocluster size (Fig. 5; Table 1).
To analyze the correlation between ErbB2 cluster size and
activation, the amount of phosphorylated and total ErbB2
were determined in parallel with its cluster size. We calcu-
lated the level of ErbB2 tyrosine phosphorylation by nor-
malizing the intensity of the antibody against phosphorylated
ErbB2 to the intensity characterizing the total amount of
ErbB2. A plot of ErbB2 tyrosine phosphorylation against
ErbB2 homocluster size shows an inverse correlation be-
tween the two parameters, both in starved and nonstarved
SKBR-3 cells (Fig. 7 A).
DISCUSSION
The potential of widely used approaches to analyze the
composition of large protein aggregates is limited. Therefore,
the unique capability of homo-FRET for measuring the size
of homoclusters makes it a valuable tool in cell biological
research (10,27,38). The fact that the relationship between
anisotropy and homocluster size is ambiguous increases the
complexity of the equations and necessitates the incorpora-
tion of simplifying assumptions into the model. Here, we
present a ﬂow-cytometric method for the quantitative anal-
ysis of protein homoclustering. The model relies on the
correlation between ﬂuorescence anisotropy and the local
FIGURE 5 Monomer percentage and cluster size of
ErbB2 in quiescent and stimulated SKBR-3 cells (A and
B) SKBR-3 cells starved in the presence of 0.1% FCS for
24 h (solid line) were stimulated with heregulin (dashed
line) or EGF (dotted line). The distributions of cluster size
(A) and monomer percentage (B) were determined by
Monte Carlo simulation, based on the anisotropy data. (C
and D) Starved SKBR-3 cells were pretreated with pertu-
zumab (solid line) and stimulated with heregulin (dotted
line). (E, F) SKBR-3 cells cultured under normal serum
conditions (10% FCS, solid line) were treated with pertu-
zumab (dotted line) and labeled with a mixture of
Alexa488-labeled and unlabeled trastuzumab IgG. SKBR-
3 cells cultured in the presence of 10% FCS were also
labeled with a mixture of Alexa488-labeled and unlabeled
trastuzumab Fab (dashed line).
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density of ﬂuorophores, and in this sense, it is similar to the
ﬂuorescence microscopic approach of Yeow and Clayton
(27). We assumed that a fraction of the investigated protein
species is monomeric, whereas other proteins of the same
species form homoclusters with a constant size. This is ob-
viously not true, but given the low number of data points and
the measurement error achievable by ﬂow-cytometric an-
isotropy measurements, this simpliﬁcation was required to
make ﬁtting of the model to measurement data possible. The
theoretical curves derived from the model show that the
shape of the anisotropy curves and the anisotropy values at
low ﬂuorophore density (low saturation) are substantially
different between different cluster sizes (Fig. 2). Therefore,
the distinct cluster sizes of ErbB1 and ErbB2, and their
changes, were reliably determined.
Emitted ﬂuorescence is split into horizontally and verti-
cally polarized components in anisotropy measurements.
In addition, the method described here involves the gradual
increase in concentration of the unlabeled antibody, at the
expense of the labeled one, leading to a decrease in ﬂuores-
cence intensity. These circumstances set a relatively high
ﬂuorescence limit for the reliable detection of cluster size by
our method. Based on extrapolation of the gradual increase of
detection error at low ﬂuorescence intensities, we estimate
that the expression level of the investigated protein has to be
;105/cell for accurate cluster-size determination. However,
the shape of the anisotropy versus saturation curve strongly
depends on the cluster size in the case of small clusters, and
the curve is signiﬁcantly different for large (N . 30) and
small clusters. These observations allow us to conclude that a
rough estimation of cluster size is possible even at lower
protein expression levels. In addition, the accuracy of mea-
surements at low ﬂuorescence intensities can be increased by
increasing the number of cells measured, which is easily
achievable in ﬂow cytometry. The fact that the total ﬂuo-
rescence intensity of a single cell is measured in ﬂow cytom-
etry, whereas it is distributed to several pixels in microscopy,
increases the signal/noise ratio in ﬂow cytometry compared
with microscopy. This circumstance makes the measurement
of dim samples more accurate in ﬂow cytometry. However,
one must not ignore the fact that subcellular resolution is not
possible in ﬂow-cytometric measurements.
Labeling of cells was usually performed using bivalent
antibodies. To minimize the possibility that antibodies cross-
link their target, labeling was performed on ice. Although
antibodies are expected to bind monovalently in the saturation
FIGURE 7 Relationship between the homoclustering of ErbB proteins and the tyrosine phosphorylation of ErbB2. (A) The normalized tyrosine
phosphorylation level of ErbB2 in starved (d) and nonstarved (s) SKBR-3 cells was determined under different conditions, and plotted against the cluster
size of ErbB2. (B) The clustering of ErbB1 (E1), ErbB2 (E2), and ErbB3 (E3) in quiescent (middle), EGF-stimulated (left), and heregulin (HRG)-stimulated
(right) cells.
FIGURE 6 Monomer percentage and cluster size of
ErbB1 in quiescent and stimulated A431 cells. A431 cells
were either cultured under normal serum conditions (10%
FCS, dotted line) or starved in the presence of 0.1% FCS for
24 h (solid line). Starved cells were stimulated with EGF
(dashed line). The distributions of cluster size (A) and
monomer percentage (B) were determined by Monte Carlo
simulation.
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concentration range used throughout the study, we performed
control experiments in which ErbB2 clusters in SKBR-3
cells labeled with trastuzumab IgG or Fab were compared.
The curves obtained using the two labeling protocols showed
remarkable overlap, indicating that labeling with bivalent IgG
did not alter the clustering properties of membrane proteins
under the labeling conditions used in the experiments.
The anisotropy of the initially excited ﬂuorophore (r1) had
to be determined for the model calculations. This anisotropy
(r1) corresponds to the anisotropy of a single, isolated, ﬂuo-
rophore-tagged antibody, which is decreased by homo-FRET
between antibodies bound to different proteins in the cluster.
We assumed that the limiting anisotropy of the antibody-
bound ﬂuorophore determined by Perrin plots is a good ap-
proximation of r1 (Fig. 4). The data could be accurately ﬁtted
by a linear equation, indicating that the limiting anisotropies
of the antibody-bound ﬂuorophore could be reliably deter-
mined. The anisotropy of a single, isolated, ﬂuorophore-
tagged antibody is smaller than the limiting anisotropy of the
ﬂuorophore because of fast hindered rotations. These rota-
tions are most likely missed by the Perrin plots, because they
are expected to cause a curvature of the leftmost part of the
graph, corresponding to very short lifetimes (FRET efﬁ-
ciencies close to 100%), which were not represented on the
plots. Therefore, the determined r1 values are smaller than the
canonical limiting anisotropy of the ﬂuorophore. However,
the anisotropy of a single ﬂuorescent antibody (emitting
ﬂuorescence depolarized by these fast rotations), and not the
canonical limiting anisotropy, is needed for Eq. 7; therefore,
the fact that r1 most likely underestimates r0 is actually a
beneﬁt. We note that homo-FRET taking place between
ﬂuorophores bound to the same antibody can be neglected,
because the number of ﬂuorophore/antibody was ;1. We
conclude that the anisotropy of the initially excited ﬂuo-
rophore needed as an input parameter for Eq. 7 could be
accurately measured.
We found in unstimulated cells that homoclusters of
ErbB2 are larger than those of ErbB1, and a lower fraction
of ErbB2 is monomeric than of ErbB1. These results imply
that ErbB2 has a higher homoclustering tendency than
ErbB1, in accordance with previous ﬁndings obtained by
classical biochemical (7,39) and FRET methods (9,40). Two
different anti-ErbB1 antibodies yielded identical results
within experimental error, giving credence to our conclusion.
Stimulation of A431 cells with EGF or serum induced an
increase in ErbB1 homocluster size and a decrease in the
percentage of monomers (Fig. 6). Although textbook dogma
supported by crystallographic data suggests that ErbB1 un-
dergoes a monomer-dimer transition upon ligand binding (2),
several studies using FRET, correlation spectroscopic, and
single molecule techniques reported higher-order ErbB1 olig-
omers in unstimulated cells, and a ligand-induced increase in
ErbB1 cluster size (13–16). The cluster sizes of 4 and 11 that
we found in quiescent and stimulated cells, respectively, are
in agreement with what was reported previously.
Ligand-induced changes in ErbB1 cluster size always have
to be interpreted in the context of the expression levels of all
ErbB proteins. Because ErbB2 is the preferred hetero-
dimerization partner of all other ErbB proteins (6), it com-
petes with them for association partners. However, A431
cells express a huge excess of ErbB1 over other ErbBs (37)
(also according to our unpublished observations). Therefore,
the ligand-induced homodimerization and homoclustering of
ErbB1 are not hindered by ErbB2.
In contrast to ErbB1, ErbB2 formed huge homoclusters
containing;100 ErbB2 proteins in unstimulated cells, which
became smaller upon stimulation with serum, EGF, or
heregulin (Fig. 5).
Very large clusters of ErbB2 containing 50 to 80 receptors
were observed by immunoelectron microscopy (41). Because
serum, EGF, and heregulin stimulation leads to ErbB2 acti-
vation, the above results imply that activated ErbB2 forms
smaller homoclusters. This assumption is corroborated by the
negative correlation between the level of ErbB2 tyrosine
phosphorylation and its cluster size (Fig. 7 A). Because
ErbB2 is a ligandless coreceptor (6), its ligand-induced ac-
tivation can only be achieved by heterodimerization with
ErbB1 or ErbB3, whose ligands are EGF and heregulin,
respectively, because ErbB4 is not expressed by SKBR-3
cells. The EGF-induced or heregulin-induced coclustering of
ErbB2 with ErbB1 or ErbB3, respectively, were reported
previously (41). We assume that ligand-binding to ErbB1 and
ErbB3 recruits ErbB2 molecules from large ErbB2 homo-
clusters, leading to diminished ErbB2 homocluster size upon
stimulation. The fact that neither EGF nor heregulin induced
any change in the monomer percentage of ErbB2 needs ex-
planation. The ErbB2 removed from large homoclusters can
redistribute to smaller clusters in which several ErbB2 pro-
teins heteroassociate with ErbB1 or ErbB3, i.e., ErbB2 will
not become monomeric. Alternatively, if ErbB2 proteins
expelled from large ErbB2 homoclusters form heterodimers
with ErbB1 or ErbB3 (regarded as monomers by our method
detecting only homoclusters), these heterocomplexes can be
removed from the membrane by the low rate of endocytosis
of ErbB2-containing heterodimers (42). If the rate of for-
mation of ErbB2 heterodimers is comparable with their en-
docytosis rate, the fraction of ErbB2 monomers will remain
constant.
Pertuzumab, an antibody sterically blocking the hetero-
dimerization of ErbB2 (43), inhibited the heregulin-induced
decrease in ErbB2 cluster size and the increase in tyrosine
phosphorylation, and slightly decreased the effect of serum
on tyrosine phosphorylation and cluster size of ErbB2 in
SKBR-3 cells. These observations follow from the inability
of ErbB2 to heterodimerize with ErbB1 or ErbB3. Conse-
quently, ErbB2 remains in large homoclusters.
Pertuzumab slightly increased the tyrosine phosphoryla-
tion of ErbB2 in starved SKBR-3 cells, accompanied by a
decrease in ErbB2 cluster size. The reciprocal change in
tyrosine phosphorylation and cluster size of ErbB2 was
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expected, based on the negative correlation between them.
However, the increased state of activation of ErbB2 was
unexpected. Our previous unpublished results from hetero-
FRET experiments showed that pertuzumab slightly blocks
ErbB2 homoassociation. In starved cells, the majority of
ErbB2 is inactive and present in large homoclusters, which are
slightly disrupted by pertuzumab. Assuming that large ErbB2
homoclusters harbor inactive proteins, the ErbB2 expelled
from these homoclusters will heterodimerize with other
membrane proteins, somehow leading to its heteroactivation.
Although the higher-order oligomers of ErbB1 and ErbB2
described here were found in cells overexpressing these
proteins, previous experimental evidence strongly indicates
that the formation of such large-scale clusters (i.e., oligomers
larger than dimers) is an inherent property of membrane
proteins (15,19,41,44,45). We believe that proteins with both
low and high expression levels form large-scale clusters, but
the number of proteins/cluster and the cluster diameter are
inﬂuenced by the expression level.
The model in Fig. 7 B integrates all these ﬁndings. The
ErbB2 homoclusters are assumed to be depots of inactive
proteins, which can be recruited by ligand-activated ErbB1 or
ErbB3 to heterodimeric complexes, explaining the observed
decrease in ErbB2 homocluster size upon activation. Because
ErbB1 is a full-featured receptor tyrosine kinase with ligand-
binding and tyrosine kinase activities, EGF not only induces
ErbB1-ErbB2 heterodimers, but also ErbB1 homodimers,
explaining the observed increase in ErbB1 homocluster size
upon EGF stimulation. However, neither ErbB2 nor ErbB3 is
a full-featured receptor tyrosine kinase, because the former
has no ligand-binding activity, whereas the latter has no ki-
nase activity. Therefore, they were likened to ‘‘the deaf and
the dumb’’ (46). It was shown that unliganded ErbB3 forms
homoclusters, which are disassembled by heregulin (18).
Integrating this observation with ours, we can envisage that
both ErbB2 and ErbB3 form large, inactive, and separate
homoclusters in unstimulated cells. Heregulin stimulation
removes ErbB3 molecules from ErbB3 homoclusters. Ligand-
activated ErbB3 recruits ErbB2 proteins from inactive ErbB2
homoclusters to ErbB2-ErbB3 heterodimers. The fact that
heregulin stimulation leads to the exclusive formation
of ErbB2-ErbB3 heterodimers, whereas EGF induces both
ErbB1 homodimers and ErbB1-ErbB2 heterodimers, ex-
plains why heregulin causes a much larger decrease in the
size of ErbB2 homoclusters. Flow-cytometric homo-FRET
measurements have the potential to shed light on the largely
unrecognized role of higher-order oligomers in transmem-
brane signaling, which will signiﬁcantly advance our un-
derstanding of the ﬁne interactions governing the ﬁrst steps of
the activation cascade of receptor tyrosine kinases.
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